PHP
RGEN icon

Parkman Healthcare Partners’s Repligen RGEN Stock Holding History

Parkman Healthcare Partners’s Portfolio RGEN Stock Details RGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,331
Closed -$2.74M – 90
2021
Q4 		$2.74M Sell
10,331
-9,669
-48% -$2.6M 0.6% 43
2021
Q3 		$5.78M Sell
20,000
-18,740
-48% -$4.81M 1.46% 23
2021
Q2 		$7.73M Buy
+38,740
New +$7.52M 1.69% 17

Other funds holding RGEN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Parkman Healthcare Partners's RGEN Position: Q1 2022 in Review

Parkman Healthcare Partners sold out of Repligen (RGEN) in Q1 2022, closing a stake of 10,331 shares — an estimated $2.74M sold.

Parkman Healthcare Partners first reported a position in RGEN in Q2 2021 and held it in 3 quarters. The position peaked at $7.73M in Q2 2021. 451 funds tracked by Wall St. Rank hold RGEN as of Q1 2022.

  • Parkman Healthcare Partners reported no remaining Repligen position as of Q1 2022 after selling out during the quarter.
  • Parkman Healthcare Partners sold 10,331 Repligen shares in Q1 2022, an estimated $2.74M.
  • Parkman Healthcare Partners first reported a position in Repligen in Q2 2021 and held it in 3 quarters.
  • Parkman Healthcare Partners's Repligen position peaked at $7.73M in Q2 2021.
  • 451 funds tracked by Wall St. Rank held Repligen as of Q1 2022.

Based on Parkman Healthcare Partners's 13F filing for Q1 2022, filed 13 May 2022.